文献速递神经免疫

儿童期起病多发性硬化肠道微生物组的宏基因组分析

Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
PubMed 文献 · Neurology · 2021-12-22

研究纳入加拿大儿童脱髓鞘疾病网络中≤21岁受试者,将20例症状 onset<18岁的多发性硬化(MS)患者按性别、年龄(±3岁)、粪便性状和种族匹配20例对照,行粪便宏基因组分析。MS组产甲烷途径患病率更高(OR 10,p=0.044)、Methanobrevibacter丰度更高(LFC 1.7,p=0.0014),同型乳酸发酵丰度更低(LFC -0.48,p=0.039);疾病修正药物暴露与产丁酸酶富集相关。

要点

  • 儿童期起病MS患者粪便宏基因组产甲烷途径患病率高于对照(OR 10,p=0.044)。
  • MS组Methanobrevibacter丰度较对照升高(LFC 1.7,p=0.0014)。
  • MS组同型乳酸发酵丰度较对照降低(LFC -0.48,p=0.039),DMD暴露与产丁酸酶富集相关。

核心结论

  • 儿童期起病MS患者与对照的肠道微生物组功能潜力和分类学存在差异,包括古菌产甲烷途径患病率更高和乳酸发酵途径耗竭。
  • 疾病修正药物暴露与产丁酸酶富集相关。
  • 这些发现提示MS患者的肠道微生物组可能存在功能潜力紊乱。

研究设计与样本

  • 研究为来自加拿大儿童脱髓鞘疾病网络的粪便样本宏基因组分析,受试者≤21岁。
  • 20例MS患者(McDonald标准,症状 onset<18岁)按性别、年龄(±3岁)、粪便性状和种族匹配20例未受累对照。
  • 从粪便样本宏基因组读数估计微生物分类学和功能潜力,按疾病状态(MS vs 对照)和疾病修正药物(DMD)暴露进行比较。

主要发现

  • MS患者症状 onset平均年龄13.6岁,其中8例未暴露于DMD。
  • 粪便采样时MS组和对照组平均年龄分别为16.1岁和15.4岁,80%为女孩。
  • 酶和蛋白质的α多样性按疾病或DMD状态无差异(p>0.20),但代谢途径、基因注释和微生物分类学有差异。
  • MS组(vs 对照)产甲烷途径患病率更高(OR 10,p=0.044),Methanobrevibacter丰度更高(LFC 1.7,p=0.0014),同型乳酸发酵丰度更低(LFC -0.48,p=0.039)。
  • 按DMD状态比较,未暴露vs暴露的MS患者磷酸丁酰转移酶更低(LFC -1.0,p=0.033)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Little is known of the functional potential of the gut microbiome in pediatric-onset multiple sclerosis (MS). We performed metagenomic analyses using stool samples from individuals with pediatric-onset MS and unaffected controls. METHODS: Persons ≤21 years old enrolled in the Canadian Pediatric Demyelinating Disease Network providing a stool sample were eligible. Twenty patients with MS (McDonald criteria) with symptom onset <18 years were matched to 20 controls by sex, age (±3 years), stool consistency, and race. Microbial taxonomy and functional potentials were estimated from stool sample-derived metagenomic reads and compared by disease status (MS vs controls) and disease-modifying drug (DMD) exposure using alpha diversity, relative abundance, and prevalence using Wilcoxon rank sum, ALDEx2, and Fisher exact tests, respectively. RESULTS: Individuals with MS were aged 13.6 years (mean) at symptom onset and 8 were DMD-naive. Mean ages at stool sample were 16.1 and 15.4 years for MS and control participants, respectively; 80% were girls. Alpha diversity of enzymes and proteins did not differ by disease or DMD status (p > 0.20), but metabolic pathways, gene annotations, and microbial taxonomy did. Individuals with MS (vs controls) exhibited higher methanogenesis prevalence (odds ratio 10, p = 0.044) and Methanobrevibacter abundance (log2 fold change [LFC] 1.7, p = 0.0014), but lower homolactic fermentation abundance (LFC -0.48, p = 0.039). Differences by DMD status included lower phosphate butyryl transferase for DMD-naive vs exposed patients with MS (LFC -1.0, p = 0.033). DISCUSSION: The gut microbiome's functional potential and taxonomy differed between individuals with pediatric-onset MS vs controls, including higher prevalence of a methane-producing pathway from Archaea and depletion of the lactate fermentation pathway. DMD exposure was associated with butyrate-producing enzyme enrichment. Together these findings indicate that the gut microbiome of individuals with MS may have a disturbed functional potential.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mirza AI, Zhu F, Knox N, et al. Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology. 2021. PMID: 34937787. doi:10.1212/WNL.0000000000013245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。